Create your blog and photo album with postbit
Create your blog and photo album

Create new post


Upload a picture:
Tags (keywords separated by comma)

Save Cancel
marijuanacard84:   Followers: 0 ; Following: 0

Medical cannabis - The controversy Rages On

medical marijuana recommendation


Marijuana is additionally known as pot, grass and weed but its formal name is really cannabis. It appears from your leaves and flowers with the plant Cannabis sativa. It can be considered a prohibited substance in the usa and lots of countries and possessing marijuana is a crime punishable by law. The FDA classifies marijuana as Schedule I, substances which have a very high risk of abuse and possess no proven medical use. Over the years several studies declare that some substances found in marijuana have medicinal use, particularly in terminal diseases including cancer and AIDS. This started a fierce debate within the advantages and disadvantages from the using medicinal marijuana. To stay this debate, the Institute of medication published the famous 1999 IOM report entitled Marijuana and Medicine: Assessing the Science Base. The report was comprehensive but didn't give you a obvious good or bad answer. The alternative camps with the medicinal marijuana issue often cite part of the report within their advocacy arguments. However, although report clarified many things, it never settled the controversy for good.

Let's consider the issues that support why medicinal marijuana ought to be legalized.

(1) Marijuana is a organic herb and it has been used from Brazilian to Asia being an herbal medicine for millennia. On this era once the natural and organic are very important health buzzwords, a organic herb like marijuana is more popular with and safer for consumers than synthetic drugs.

(2) Marijuana has strong therapeutic potential. Several studies, as summarized from the IOM report, have observed that cannabis can be used as analgesic, e.g. to help remedy pain. Several studies indicated that THC, a marijuana component works for treating chronic pain gone through by cancer patients. However, studies on acute pain including those experienced during surgery and trauma have inconclusive reports. A couple of studies, also summarized from the IOM report, have indicated that some marijuana components have antiemetic properties and are, therefore, effective against nausea and vomiting, which can be common unwanted side effects of cancer chemotherapy and radiation therapy. Some researchers think that cannabis has some therapeutic potential against neurological diseases such as ms. Specific compounds purchased from marijuana have strong therapeutic potential. Cannobidiol (CBD), an important component of marijuana, may have antipsychotic, anticancer and antioxidants. Other cannabinoids have been shown to prevent high intraocular pressure (IOP), a significant risk factor for glaucoma. Drugs that includes active ingredients seen in marijuana but have already been synthetically manufactured in the laboratory are already approved by the US FDA. To illustrate Marinol, an antiemetic agent indicated for nausea and vomiting related to cancer chemotherapy. Its active ingredient is dronabinol, an artificial delta-9- tetrahydrocannabinol (THC).

(3) One of the leading supporters of medicinal marijuana may be the Marijuana Policy Project (MPP), a US-based organization. Many medical expert societies and organizations have expressed their support. As one example, The American College of Physicians, recommended a re-evaluation of the Schedule I classification of marijuana within their 2008 position paper. ACP also expresses its strong support for research into the therapeutic role of marijuana and also exemption from federal justice; civil liability; or professional sanctioning for physicians who prescribe or dispense medical cannabis according to state guiidelines. Similarly, defense against criminal or civil penalties for patients using medicinal marijuana as permitted under state laws.

(4) Medical marijuana is legally used in many western world The argument of whether they can take action, have you thought to us? is an additional forte. Some countries, including Canada, Belgium, Austria, the low countries, great britain, Spain, Israel, and Finland have legalized the therapeutic utilization of marijuana under strict prescription control. Some states in the US will also be allowing exemptions.

Now listed here are the arguments against medicinal marijuana.

(1) Deficiency of data on safety and efficacy. Drug regulation will depend on safety first. The protection of marijuana and its components still has to first be established. Efficacy only comes second. Even when marijuana has some beneficial health effects, the advantages should outweigh the potential for loss it to be considered for medical use. Unless marijuana is known as better (safer and more effective) than drugs currently available on the market, its approval for medical use may be a long shot. According to the testimony of Robert J. Meyer with the Department of Health and Human Services having access to a medication or medical treatment, not understanding utilizing it or even whether it is effective, does not benefit anyone. Simply having access, not having safety, efficacy, and adequate use information will not help patients.

(2) Unknown chemical components. Medical cannabis can only often be accessible and cost-effective in herbal form. Like other herbs, marijuana falls beneath the class of botanical products. Unpurified botanical products, however, face many problems including lot-to-lot consistency, dosage determination, potency, shelf-life, and toxicity. According to the IOM report if you have any way ahead for marijuana as being a medicine, it is in its isolated components, the cannabinoids along with their synthetic derivatives. To fully characterize different components of marijuana would cost much time and expense the costs with the medications that will emerge from it will be way too high. Currently, no pharmaceutical company seems thinking about investing money to isolate more therapeutic aspects of marijuana beyond precisely what is already available for sale.

(3) Potential for abuse. Marijuana or cannabis is addictive. It may not be as addictive as hard drugs like cocaine; but it surely cannot be denied that there is a risk of abusing drugs linked to marijuana. It is been demonstrated by a few studies as summarized inside the IOM report.

(4) Not enough a secure delivery system. The most frequent kind of delivery of marijuana is by smoking. Thinking about the current trends in anti-smoking legislations, this type of delivery should never be approved by health authorities. Reliable and safe delivery systems by means of vaporizers, nebulizers, or inhalers are still on the testing stage.

(5) Symptom alleviation, not cure. Even when marijuana has therapeutic effects, it is just addressing the symptoms of certain diseases. No treat or cure these illnesses. Given that it can be effective against these symptoms, there are already medications available which work equally well as well as, devoid of the side effects and probability of abuse related to marijuana.

The 1999 IOM report can't settle the debate about medicinal marijuana with scientific evidence offered by that time. The report definitely discouraged the application of smoked marijuana but gave a nod towards marijuana use via a medical inhaler or vaporizer. In addition, the report also recommended the compassionate utilization of marijuana under strict medical supervision. Furthermore, it urged more funding from the research of the safety and efficacy of cannabinoids.

Precisely what stands with respect to clarifying the questions raised by the IOM report? The medical authorities usually do not appear to be interested in having another review. There is limited data available and whatever can be acquired is biased towards issues of safety around the uncomfortable side effects of smoked marijuana. Data on efficacy mainly result from studies on synthetic cannabinoids (e.g. THC). This disparity in data bakes an objective risk-benefit assessment difficult.

Clinical tests on marijuana are few and difficult to conduct on account of limited funding and strict regulations. Due to complicated legalities involved, not many pharmaceutical information mill investing in cannabinoid research. Most of the time, it's not at all clear the best way to define medical cannabis as advocated and opposed by many groups. Will it only talk about using the botanical product marijuana or should it include synthetic cannabinoid components (e.g. THC and derivatives) also? Synthetic cannabinoids (e.g. Marinol) available in the market can be extremely expensive, pushing people for the cheaper cannabinoid in the form of marijuana. Obviously, the thing is further clouded by conspiracy theories relating to the pharmaceutical industry and drug regulators.

cannabis card

Post by marijuanacard84 (2016-07-31 05:31)

Post your comment:

Name: Email: Site:

| Explore users | New posts | Create your blog | Create your photo album |
| About Postbit | Our blog | Terms of use | Contact Postbit |

Copyright © 2019 -